Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-10: ivonescimab versus durvalumab consolidation after concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
CTR20263641Phase 3Active
- Sponsor
- CTTQ-Akeso
- Start
- Oct 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab, durvalumab in non-small cell lung cancer (NSCLC), sponsored by CTTQ-Akeso. Started Oct 2026; status: active.
02
Drugs
ivonescimabdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263641.